McCarthy Matthew W
Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Expert Opin Pharmacother. 2023 Sep-Dec;24(17):1839-1843. doi: 10.1080/14656566.2023.2262387. Epub 2023 Nov 12.
On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health opened enrollment for RECOVER-Vital, a randomized study to evaluate new treatment options for long Coronavirus (long COVID).
The RECOVER Initiative is a $1.15 billion research platform intended to describe, categorize, treat, and prevent long-term symptoms following infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2), the virus that causes Coronavirus (COVID-19). More than 200 symptoms have been associated with long COVID, potentially affecting nearly all body systems, and current estimates suggest that between 7 million and 23 million Americans have developed long COVID. However, there are no approved treatments for this condition.
The first prospective, randomized study of the RECOVER research initiative, RECOVER-Vital, will evaluate the SARS-CoV-2 antiviral nirmatrelvir/ritonavir (Paxlovid) as a potential treatment for long COVID. This manuscript explores what is known about Paxlovid to treat and prevent long COVID and examines the rationale for addressing this condition with an antiviral agent.
2023年7月31日，美国卫生与公众服务部宣布成立“长新冠研究与实践办公室”，美国国立卫生研究院开启了RECOVER-Vital研究的受试者招募工作，这是一项随机研究，旨在评估针对长新冠的新治疗方案。
“恢复（RECOVER）计划”是一个耗资11.5亿美元的研究平台，旨在描述、分类、治疗和预防由严重急性呼吸综合征冠状病毒2（SARS-CoV-2，即导致新冠的病毒）感染后的长期症状。超过200种症状与长新冠相关，可能影响几乎所有身体系统，目前估计有700万至2300万美国人出现了长新冠症状。然而，针对这种情况尚无获批的治疗方法。
“恢复（RECOVER）研究计划”的首个前瞻性、随机研究RECOVER-Vital，将评估SARS-CoV-2抗病毒药物奈玛特韦/利托那韦（帕罗韦德）作为长新冠潜在治疗方法的效果。本文探讨了关于帕罗韦德治疗和预防长新冠的已知信息，并研究了使用抗病毒药物治疗这种疾病的基本原理。
